Artemis Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Artemis Therapeutics, Inc.
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions, providing comprehensive transaction coverage from 1991 to the present.
Our monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.
Israel's Obecure is investigating the potential of a marketed compound, betahistine, in obesity. It's hoping this repositioning approach will both accelerate timelines and help it overcome growing drug safety hurdles.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.